Abstract
HIV infection is one of the most dangerous and widespread infectious diseases in the world. According to the latest update from the Joint United Nations Program on HIV/AIDS, as of 2021, the number of people living with HIV infection was 38.4 million, and the number of new infections reached 1.5 million. [1] In Russia, according to Rosstat, the incidence of HIV infection increased by more than 20 % in January 2023, compared to January 2022. This means that the problem of HIV infection is still relevant, and additional efforts are required to combat this disease. Due to the development of medicine and pharmacology, new prospects have now emerged in the treatment of HIV infections. This paper examines the results of clinical trials of drugs that open up new opportunities in the fight against HIV infection. The authors set out to examine the latest advances in the treatment of HIV infection based on the results of clinical drug trials over the past 5 years.
Publisher
PANORAMA Publishing House
Subject
General Medicine,General Earth and Planetary Sciences,General Environmental Science,General Medicine,Ocean Engineering,General Medicine,General Medicine,General Medicine,General Medicine,General Earth and Planetary Sciences,General Environmental Science,General Medicine
Reference30 articles.
1. 1. UNAIDS [Internet]. [cited 2023 Dec 13]. Available from: https://www.unaids.org/en
2. 2. Infektsionnye bolezni: natsionalnoe rukovodstvo [Infectious diseases: national guidelines] / eds. N.D. Iushchuk, Iu. Ia. Vengerov. - 2nd ed., revised and expanded. - M.: GEOTAR-Media, 2018. - 1104 p. - (Series «National Guidelines»). (In Russ.)
3. 3. Farmakologiia [Pharmacology] / Ed.R. N. Aliautdin. - 2nd ed., rev. - M.: GEOTAR-MED, 2004. - 592 p.: il. (In Russ.)
4. 4. Barroso S, Morén C, González-Segura À, Riba N, Arnaiz JA, Manriquez M, et al. Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers. PLoS One. 2019;14 (5):e0216712.
5. 5. Gaur AH, Cotton MF, Rodriguez CA, McGrath EJ, Helström E, Liberty A, et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial. Lancet Child Adolesc Health. 2021 Sep;5 (9):642-51.